Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report
The Company stated that the ASX remains its primary listing and home market, while the proposed OTCID quotation is designed to provide US-based investors with a more familiar and accessible pathway to trade Audeara securities. Importantly, the proposed quotation does not involve a capital …
The company confirmed no dividends were paid, recommended or declared during the current or previous financial period. Net tangible assets per ordinary security were 0.68 cents at 30 June 2026, down from 1.14 cents in the prior corresponding period, with the company noting that …
Under the terms agreed, it is intended that the proposed merger will be implemented through a Scheme of Arrangement under which Genetic Signatures will acquire 100 percent of Microba'sIssued Sharesand options. Microba shareholders will receive 0.654 new Genetic Signatures shares for each Microba share …
Rhythm Biosciences (ASX:RHY) has reached the first milestone in the independent assessment of its ColoSTAT blood-based bowel cancer test in England. The Southern Hub Research Team, based at the Royal Surrey NHS Foundation Trust and part of the NHS Berkshire and Surrey Pathology Services …
• Ansell makes protective gloves and clothing for industrial and healthcare use, consumable products that customers buy repeatedly.
• The US Food and Drug Administration approved Telix's brain-cancer imaging agent Pixclara in September 2026, adding a new product to.
Cochlear (ASX:COH) is the world's leading maker of cochlear implants — devices that restore a sense of sound to people with severe hearing loss — and a member of the S&P/ASX 200 health care sector. ItsBusinesshas two parts: implanting devices in new recipients, and, …
Sonic Healthcare (ASX:SHL) is one of the world's largest medical-diagnostics companies and a member of the S&P/ASX 200 health care sector. Its coreBusinessis pathology — the laboratory testing of blood, tissue and other samples that doctors order to diagnose and monitor illness. Every day, …
Under the final rule, CMS reassigned eligible WiSE procedures from Medicare Severity Diagnosis Related Groups (MS-DRGs) 242 and 244 to MS-DRGs 228 and 229 respectively. The company says the higher-value categories align with leadless pacemaker procedures, and that CMS stated in its final rule …
The A$0.62 issue price is a 15.1% discount to the last traded price and an 11.4% discount to the five-dayVolumeweighted average price. Participants receive, for nil consideration, three attachingOptionsfor every four new CDIs subscribed for, each with an exercise price of A$0.93 and expiring …
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Start Your 7-Days Free Trial Today!
Hi! How can we help you today?
Loading…